RE:RE:RE:RE:Looks like best-case predictions are coming trueUnless I missed something, I believe that the topic of tax-loss selling deadlines is unrelated to the original post. Anyway, I do appreciate this tidbit of important info. For everyone's convenience, the relevant excerpt from the IRS reference document is as follows:
Securities traded on an established market.
For securities traded on an established securities market, your holding period begins the day after the trade date you bought the securities, and ends on the trade date you sold them.
.
Do not confuse the trade date with the settlement date, which is the date by which the stock must be delivered and payment must be made..
Example.
You are a cash method, calendar year taxpayer. You sold stock on December 31, 2020. According to the rules of the stock exchange, the sale was closed by delivery of the stock and payment of the sale price in January 2021. You received payment of the sale price on that same day. Report your gain or loss on your 2020 return, even though you received the payment in 2021. The gain or loss is long term or short term depending on whether you held the stock more than 1 year. Your holding period ended on December 31.
GLTA!
Nailbiter1 wrote: For Canada, the last day for tax-loss selling in 2021 is
December 29.
Stocks purchased or sold after this date will be settled in 2022, so any capital gains or losses will apply to the 2022 tax year.
The system differs in the US, and based on information from the IRS, the last day for tax-loss selling this year is December 31.
jopatclo wrote: Last Day for Tax loss selling is today Dec29th !!
NewToInvesting7 wrote: Was it confirmed that StageZero is one of the PCR testing companies that are suffering backlog, ad/or unprecedented demand for its PCR tests? Would be nice if it is one of those companies, since we were told that they have a daily capacity of 3,000 tests (if I recall correctly). Otherwise we are all just guessing at the revenues.
Significant Covid testing revenues in Q4 would be great to help with operating expenses, but it’s the cancer testing that I most look forward to. Hoping it would at least be between $650k-$1m in Q4.
Regardless, for me personally, I've connected with Matt (COO), and am comfortable that this company will do well in the years ahead. Matt appears to have a level head, and can execute on James' vision, something that James struggled with (at least from my limited POV). Hope to see this on a nice steep upwards movement mid-late 2022.
Cheers!
gojotv! wrote: The unprecedented demand for Covid tests (backlogs reported) will provide that nice, thick, revenue runway for the growth of Aristotle testing and the international deployment of Care Oncology's treatment protocol.
The fact that the "targets" have been reached (or will soon) bodes well for the next financials.
Expect a great New Year's surprise!
Cheers, and Happy Holidays!